文献速递前列腺癌

转移性去势抵抗性前列腺癌局部区域治疗对疾病进展的影响:一项多中心队列的真实世界经验

The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-12-02

这项前瞻性多中心真实世界队列纳入117例未接受化疗的转移性去势抵抗性前列腺癌(mCRPC)患者,接受阿比特龙(AA)或恩扎卢胺(EZ)一线或二线治疗。中位随访期间,低肿瘤负荷患者无进展生存(PFS)概率更高(log rank p=0.009),且该亚组接受局部区域治疗对PFS有显著影响(p=0.048);高肿瘤负荷患者中局部区域治疗对PFS影响可忽略。

要点

  • 低肿瘤负荷mCRPC患者的PFS概率显著高于高肿瘤负荷患者(log rank p=0.009)。
  • 低肿瘤负荷亚组中,局部区域治疗对PFS有显著影响(p=0.048)。
  • 全队列及高肿瘤负荷患者中,局部区域治疗对PFS的影响可忽略(p=0.6和p=0.75)。

核心结论

  • 低肿瘤负荷mCRPC患者PFS概率更高,似乎可从局部区域治疗中获益。

研究设计与样本

  • 前瞻性、多中心、纵向真实世界队列研究,纳入2012年10月至2020年11月期间5个中心收治的未接受化疗的mCRPC患者,接受AA或EZ作为一线或二线治疗。
  • 共117例未接受化疗的mCRPC患者接受一线治疗,其中57例(48.7%)接受AA,60例(51.3%)接受EZ;8例(6.7%)在一线治疗失败后接受挽救性化疗;28例转为二线治疗。
  • mCRPC起病时高肿瘤负荷定义为:阳性淋巴结≥5 cm或骨转移灶超过6处。

主要发现

  • 2年无进展生存概率、癌症特异性生存概率和总生存概率分别为65.5%、82.2%和78.4%。
  • 自mCRPC诊断以来,25例患者出现寡进展,其中23/25(92%)接受立体定向放射治疗(针对4个淋巴结部位和19个骨部位),2/25(8%)接受挽救性淋巴结清扫。
  • Kaplan-Meier分析显示,低肿瘤负荷患者PFS概率更高(log rank p=0.009);在该亚组中,局部区域治疗对PFS有显著影响(p=0.048)。
  • 在全队列和高肿瘤负荷患者中,局部区域治疗对PFS的影响可忽略(分别为p=0.6和p=0.75)。

临床怎么用

  • 作者认为,低肿瘤负荷mCRPC患者似乎可从局部区域治疗中获益(原文结论)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Available data on medical treatment of metastatic castration resistant prostate cancer (mCRPC) support the use of more than one therapy line to delay chemotherapy. We evaluate in a longitudinal real life multicenter cohort, the oncological outcome of mCRPC patients treated with Abiraterone Acetate (AA) and Enzalutamide (EZ) in a chemo-naïve setting, who received locoregional treatments for subsequent development of oligorecurrent disease. METHODS: We prospectively collected data on chemo-naïve mCRPC patients, who received either AA or EZ as first or second line treatment between Oct-2012 and Nov-2020 at 5 centers. High-volume disease at mCRPC onset was defined as bulky positive nodes (≥5 cm) or more than 6 bone metastases. Survival probabilities were computed at 12, 24, 48 and 60 months after treatment start. The impact of loco-regional treatments on progression free survival (PFS) were assessed with the Kaplan-Meier method and the log-rank test was applied. RESULTS: Overall, 117 chemo-naive mCRPC patients received a first line therapy. Fifty-seven (48.7%) patients received AA and 60 (51.3%) received EZ. Eight (6.7%) patients underwent salvage chemotherapy after first line failure. Overall, 28 patients shifted to a second line therapy. Two-yr progression-free, cancer-specific and overall survival probabilities were 65.5%, 82.2% and 78.4% respectively. Since diagnosis of mCRPC, oligo progression occurred in 25 patients who received stereotactic radiation therapy (23/25, 92%) focused on metastasis (4 nodal sites and 19 bones) or salvage lymph node dissection (2/25, 8%). At Kaplan-Meier analysis, patients with low volume disease displayed higher PFS probabilities (log rank p = 0.009) and in this subgroup of patients loco-regional treatments had a significant impact on PFS (p = 0.048), while it was negligible in the whole cohort and in patients with high volume disease (p = 0.6 and p = 0.75). CONCLUSIONS: Low-volume mCRPC patients are exposed to improved PFS and seem to benefit from locoregional treatments.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ferriero M, Prata F, Mastroianni R, et al. The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort. Prostate Cancer Prostatic Dis. 2022. PMID: 36460734. doi:10.1038/s41391-022-00623-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。